Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral939.1%
Bearish14.4%
IDEXX Laboratories, Inc. · IDXX · FY2024 Q3 · Calendar Q4 2024
IDEXX: Growth Holds, but U.S. Headwinds Lower the Outlook
The quarter supports a mixed view: recurring diagnostic demand, customer retention and product innovation remain constructive, but the lowered outlook shows that near-term U.S. clinic-volume and weather pressures are offsetting part of that strength.
Reported Before market openNASDAQHealthcare
$44.15B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.80
Consensus $2.68
EPS surprise
+4.5%
Reported versus consensus
Reported revenue
$975.5M
Consensus $980.3M
Revenue surprise
-0.5%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-9.8%
Event window
SPY move
-2.0%
Same window
Abnormal move
-7.8%
Stock minus SPY
Volume
3.4×
Versus trailing sessions
Subsequent drift
+3.6%
Up to 20 sessions
IDXXSPY benchmark
Ask FN2 about IDXX FY2024 Q3
Transcript, numbers and history already loaded
Why did IDXX fall 9.8% after beating EPS estimates in FY2024 Q3?What changed in IDXX's guidance and outlook in FY2024 Q3?Give me the bull and bear case for IDXX after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the company moved from a lower-end full-year growth outlook to a more specific 5.3%-6% organic-growth range and 5.8%-6.4% CAG recurring-growth range. The current analysis also emphasizes the InView Dx order pipeline, Velo expansion and the cancer-screening roadmap, while pricing normalization and clinic visits remain key questions.
Guidance delta
Management lowered full-year organic revenue growth guidance to 5.3%-6% and CAG diagnostic recurring growth guidance to 5.8%-6.4%, citing U.S. macro pressure and severe-weather impacts.
Key takeaways
- Q3 organic revenue growth was 6%, supported by CAG diagnostic recurring revenue and a 13% increase in the water business.
- Premium instrument placements and a high-retention installed base continue to support recurring revenue, while instrument revenue declined from a prior-year peak.
- Management highlighted InView Dx, Catalyst Pancreatic Lipase, Velo and the Cancer Diagnostic Screening Panel as pipeline supports.
Management priorities
- Execute the InView Dx Analyzer launch and broaden shipments.
- Expand Catalyst Pancreatic Lipase and Velo adoption.
- Continue software enhancements, cloud-native extensions and the cancer-screening-panel rollout.
Follow IDXX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$560.36Current
$247Low
$643.33Average
$830High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 19, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 16, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 11, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Stifel | Buy | Buy | Maintain | Mar 31, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 9, 2026 |
| BTIG | Buy | Buy | Maintain | Feb 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Jul 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 21, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 17, 2024 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Aug 2, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 13, 2021 |
| Guggenheim | Neutral | Buy | Downgrade | Jul 12, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | May 2, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 2, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 16, 2018 |
| Aegis Capital | Sell | Sell | Maintain | Jun 1, 2017 |
| CL King | Neutral | Neutral | Maintain | Apr 1, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Aug 28, 2015 |
| Feltl & Co. | Hold | Sell | Upgrade | Jul 23, 2015 |
| Bank oferica | Buy | Buy | Maintain | Apr 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $560.36. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Goldman Sachs | Matt Dellatorre | $740 | $547.18 | +32.1% | Oct 16, 2026 |
| Barclays | Glen Santangelo | $710 | $595.76 | +26.7% | Aug 11, 2026 |
| UBS | Analyst unavailable | $620 | $559.86 | +10.6% | Jul 27, 2026 |
| UBS | Andrea Alfonso | $640 | $569.17 | +14.2% | Apr 28, 2026 |
| Piper Sandler | Analyst unavailable | $750 | $644.61 | +33.8% | Feb 9, 2026 |
| Barclays | Glen Santangelo | $800 | $642.94 | +42.8% | Feb 5, 2026 |
| UBS | Andrea Alfonso | $730 | $639.6 | +30.3% | Feb 3, 2026 |
| BTIG | Analyst unavailable | $800 | $639.6 | +42.8% | Feb 3, 2026 |
| Barclays | Glen Santangelo | $850 | $706.65 | +51.7% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $805 | $721.04 | +43.7% | Nov 4, 2025 |
| UBS | Analyst unavailable | $750 | $722.94 | +33.8% | Nov 4, 2025 |
| BTIG | Analyst unavailable | $830 | $722.94 | +48.1% | Nov 4, 2025 |
| Jefferies | Keith Devas | $830 | $722.94 | +48.1% | Nov 4, 2025 |
| Leerink Partners | Analyst unavailable | $785 | $722.94 | +40.1% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $775 | $722.94 | +38.3% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $700 | $628.54 | +24.9% | Oct 31, 2025 |
| UBS | Andrea Alfonso | $720 | $638.89 | +28.5% | Oct 1, 2025 |
| Morgan Stanley | Analyst unavailable | $722 | $641.94 | +28.8% | Aug 5, 2025 |
| BTIG | Analyst unavailable | $785 | $641.94 | +40.1% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $640 | $682.78 | +14.2% | Aug 4, 2025 |
| Stifel Nicolaus | Jonathan Block | $510 | $495.73 | -9.0% | Jun 24, 2024 |
| Barclays | Analyst unavailable | $590 | $507.68 | +5.3% | Feb 8, 2023 |
| J.P. Morgan | Analyst unavailable | $550 | $487.04 | -1.8% | Feb 7, 2023 |
| Atlantic Equities | Analyst unavailable | $600 | $485.53 | +7.1% | Feb 7, 2023 |
| Oppenheimer | Analyst unavailable | $247 | $483.2 | -55.9% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $268 | $483.2 | -52.2% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $273 | $420.63 | -51.3% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $543 | $435.78 | -3.1% | Nov 15, 2022 |
| Stifel Nicolaus | Analyst unavailable | $500 | $355.62 | -10.8% | Jun 24, 2022 |
| Goldman Sachs | Analyst unavailable | $530 | $357.33 | -5.4% | May 19, 2022 |
| Barclays | Balaji Prasad | $700 | $364.5 | +24.9% | May 6, 2022 |
Track every rating change on IDXX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services.…
Historical context
All IDXX earningsLatest beats and misses
Who reports nextBeat on EPS
Get the IDXX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-18T23:20:43.791725+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-18T23:20:43.788979+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-18. For educational purposes only; not investment advice.